Sarah brings investment and board experience in Scottish healthcare and deep tech companies, following roles with Archangels and the Roslin Foundation.
The round was led by Archangels, Par Equity, and Scottish Enterprise to accelerate product development and international growth.
"This investment reflects the growing recognition of the critical need for innovative communication solutions in the underwater IoT sector. The support from our investors will allow us to scale our operations, enhance our product offerings and help industries worldwide manage their resources more effectively. We are grateful for their trust and excited to shape the future of underwater communication."
The seed round was led by Blackfinch Ventures to support global growth and commercial adoption.
"This investment marks a significant step forward as we continue pioneering new applications for magnetic sensing. With the support of our investors, we are expanding our team, advancing our technology, and bringing our solutions closer to widespread adoption."
The investment round was led by Archangels with participation from Dr Yusuf Hamied, British Business Investments, and seed investors.
"Our DPI has the potential to become the simplest, most convenient single-dose, disposable inhaler on the market, revolutionising the delivery of critical drugs, without the cost and environmental impact of existing devices."
The investment round was led by Archangels to help the life science firm advance its cell analysis platform.
"We are uniquely positioned in harnessing the power of consumer electronics technology to meet the emerging, complex needs of the bioprocess industry. On the back of a very successful year for Cytomos, this new funding will now allow us to scale up our engagement with industry partners. We truly believe that, through our CDS technology, we offer a powerful platform which will help the scientific community bring novel therapies to market faster and radically reduce costs by making better informed, game-changing decisions a lot earlier."
The funding round was led by Archangels to support product development and US commercialisation.
"Bioliberty has developed a highly effective solution for helping patients with hand weakness, with the potential to improve the quality of life for millions worldwide. We believe its technology has far-reaching benefits beyond this first application, providing the business with an excellent opportunity to grow quickly from its base here in Scotland. Archangels is excited to be supporting the team as they finalise what we hope will be the first of many products and start scaling up their sales activity."
The funding round was led by Archangels to support international expansion and product development.
"In a post-pandemic world, web-based clinical triage is becoming an increasingly an important part of how healthcare is delivered in the UK and globally, providing a vital service and reducing the burden on healthcare teams. I have no doubt that the clinical depth of the PhysioWizard product, which has been developed over many years, will ensure that it becomes the leading digital triage solution not only in the UK but globally."
Archangels has backed Earth Blox in a £1.5m seed round to support product development and market expansion.
"We are very pleased to secure this funding from Archangels and join a strong portfolio of businesses in the life sciences and tech sectors. Investment into innovative businesses like ours is vital to growth in all areas, from customer acquisition to building a great team. This investment will help us develop Earth Blox as a scalable SaaS and get the power of Earth observation insights into the hands of a range of users around the world."
The funding round was led by Archangels with participation from the Scottish Investment Bank and company insiders.
"Our technology roadmap is all about empowering companies with real life insight to the risks their employees face at work. The added ability to help companies and their workers get back to work safely by helping them to maintain a safe distance from each other is another string to our bow and I’m proud of the team that has developed this facility in such a short space of time. It has caught the attention of the media and of hundreds of companies who are wrestling with the restrictions that are being placed on all of us as a consequence of the Coronavirus crisis."
The Edinburgh medical device firm secured backing from Archangels and the Scottish Investment Bank to prepare for its American market entry.
"We are delighted by the continuing commitment of our existing investors in this financing. This new investment allows us to continue to execute our strategy as we anticipate PMA approval for our CALCIVIS Imaging System later this year from FDA. We remain very confident in the potential of this new approach to preventive dentistry in the US, when it is launched in the world’s largest dentistry market in 2020. This optimism has been reinforced by our experience in the UK, where the CALCIVIS Imaging System has been shown to provide reliable, visualisation of demineralisation enabling bespoke, evidence-based preventive treatment for dental caries patients."
NVM Private Equity led the investment round with participation from Archangels and the Scottish Investment Bank.
"Our investors are a key part of our team, and I’m delighted to have NVM join us on the journey as we work together to build a company focussed on delivering success for our customers."
